Last reviewed · How we verify
NgG medium dose investigational vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
NgG medium dose investigational vaccine (NgG medium dose investigational vaccine) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NgG medium dose investigational vaccine TARGET | NgG medium dose investigational vaccine | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NgG medium dose investigational vaccine CI watch — RSS
- NgG medium dose investigational vaccine CI watch — Atom
- NgG medium dose investigational vaccine CI watch — JSON
- NgG medium dose investigational vaccine alone — RSS
Cite this brief
Drug Landscape (2026). NgG medium dose investigational vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ngg-medium-dose-investigational-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab